Summary
Vanda Pharmaceuticals Inc (Vanda Pharmaceuticals) is a specialty pharmaceutical company that develops and commercializesnovel therapiesfor the treatment of central nervous system disorders. The company’s products include Hetlioz, a melatonin receptor agonist for the treatment of non-24-hour sleep-wake disorder; Fanapt, an atypical antipsychotic for the treatment of schizophrenia in adults. The company's pipeline products comprise VLY-686, a small molecule neurokinin-1 receptor antagonist for pruritus in atopic dermatitis;AQW051, an alpha-7 nicotinic acetylcholine receptor for CNS disorders; Trichostatin A for oncology indications; and others. Vanda Pharmaceuticals is headquartered in Washington D.C., the US.
Vanda Pharmaceuticals Inc (VNDA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Vanda Pharma Enters into Licensing Agreement with UC San Francisco 10
Novartis Pharma Enters into Licensing Agreement with Vanda Pharma for AQW-051 11
Vanda Pharma Enters Into Licensing Agreement With Eli Lilly For VLY-686 12
Vanda Pharma Enters Into Licensing Agreement With MegaPharm For Fanapt 13
Vanda Pharma Enters Into Licensing Agreement With Biotoscana Farma For Fanapt 14
Vanda Pharma Enters Into Licensing Agreement With Probiomed For Fanapt 15
Equity Offering 16
Vanda Pharma Raises USD25 Million in Private Placement of Common Stock 16
Vanda Pharma Raises USD66.7 Million in Public Offering of Shares 18
Vanda Pharma Completes Public Offering Of Shares For US$52 Million 20
Acquisition 22
Vanda Pharma May Sell Itself 22
Vanda Pharmaceuticals Inc - Key Competitors 23
Vanda Pharmaceuticals Inc - Key Employees 24
Vanda Pharmaceuticals Inc - Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Aug 02, 2017: Vanda Pharmaceuticals Reports Second Quarter 2017 Financial Results 26
May 02, 2017: Vanda Pharmaceuticals Reports First Quarter 2017 Financial Results 27
Feb 15, 2017: Vanda Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results 28
Jan 09, 2017: Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2016 Revenue Results and 2017 Financial Guidance 29
Nov 02, 2016: Vanda Pharmaceuticals Reports Third Quarter 2016 Financial Results 30
Jul 27, 2016: Vanda Pharmaceuticals Reports Second Quarter 2016 Financial Results 31
May 04, 2016: Vanda Pharmaceuticals Reports First Quarter 2016 Financial Results 32
Feb 10, 2016: Vanda Pharmaceuticals Reports Fourth Quarter 2015 and Full Year 2015 Financial Results 33
Jan 11, 2016: Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2015 Results and 2016 Financial Guidance 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35
List Of Tables
List of Tables
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Vanda Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Vanda Pharma Enters into Licensing Agreement with UC San Francisco 10
Novartis Pharma Enters into Licensing Agreement with Vanda Pharma for AQW-051 11
Vanda Pharma Enters Into Licensing Agreement With Eli Lilly For VLY-686 12
Vanda Pharma Enters Into Licensing Agreement With MegaPharm For Fanapt 13
Vanda Pharma Enters Into Licensing Agreement With Biotoscana Farma For Fanapt 14
Vanda Pharma Enters Into Licensing Agreement With Probiomed For Fanapt 15
Vanda Pharma Raises USD25 Million in Private Placement of Common Stock 16
Vanda Pharma Raises USD66.7 Million in Public Offering of Shares 18
Vanda Pharma Completes Public Offering Of Shares For US$52 Million 20
Vanda Pharma May Sell Itself 22
Vanda Pharmaceuticals Inc, Key Competitors 23
Vanda Pharmaceuticals Inc, Key Employees 24
Vanda Pharmaceuticals Inc, Subsidiaries 25
List Of Figures
List of Figures
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
